Intralymphatic Immunotherapy: Update and Unmet Needs

Gabriela Senti, Andreas U. Freiburghaus, Désirée Larenas-Linnemann, Hans Jürgen Hoffmann, Amber M. Patterson, Ludger Klimek, Danilo Di Bona, Oliver Pfaar, Lars Ahlbeck, Mübeccel Akdis, Dan Weinfeld, Francisco A. Contreras-Verduzco, Alvaro Pedroza-Melendez, Søren H. Skaarup, Sang Min Lee, Lars Olaf Cardell, Johannes M. Schmid, Ulla Westin, Ralph Dollner, Thomas M. Kündig

Research output: Contribution to journalArticlepeer-review


Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT) or oral (OIT) application of allergen preparations. This is an up-to-date review of the clinical evidence for a novel route of allergen application, i.e., directly into lymph nodes - intralymphatic immunotherapy (ILIT). The major advantages of ILIT over the current AIT approaches are its short duration and the low allergen doses administered. The whole treatment consists of merely 3 ultrasound-guided injections into inguinal lymph nodes 1 month apart. While the number of patients included in randomised controlled trials is still limited, the clinical results for ILIT are encouraging, but more clinical trials are needed, as well as more preclinical work for optimising formulations.

Original languageEnglish
Pages (from-to)141-149
JournalInternational Archives of Allergy and Immunology
Issue number2
Early online date2018 Nov 2
Publication statusPublished - 2019
Externally publishedYes

Subject classification (UKÄ)

  • Respiratory Medicine and Allergy

Free keywords

  • Allergen-specific immunotherapy
  • Allergy
  • Clinical trials
  • Intralymphatic immunotherapy


Dive into the research topics of 'Intralymphatic Immunotherapy: Update and Unmet Needs'. Together they form a unique fingerprint.

Cite this